HER2 breast cancer therapies: a review
Conleth G Murphy, Shanu ModiBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been...
Guardado en:
Autores principales: | Conleth G Murphy, Shanu Modi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3a73e9c2eef24772a3f1de13accb894c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bevacizumab in the treatment of HER2-negative breast cancer
por: Vito Lorusso
Publicado: (2008) -
Current neoadjuvant treatment options for HER2 positive breast cancer
por: Abdel-Razeq H, et al.
Publicado: (2011) -
Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Bella Kaufman, et al.
Publicado: (2008) -
Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer
por: Sun JZ, et al.
Publicado: (2014) -
Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer
por: Thomas Kunzke, et al.
Publicado: (2021)